Navigation Links
Calvert Research and Auburn University Announce Joint Venture
Date:10/24/2008

Strategic partnership focuses on target drug delivery.

Cary, NC (PRWEB) October 24, 2008--Calvert Research, LLC (a Calvert Holdings, Inc. company) and Auburn University announced today a joint research project entitled, Targeted Drug Delivery. Undertaken through Auburn University College of Veterinary Medicine's Department of Pathobiology, the six-month study is under the direction of Dr. Valery Petrenko. Dr. Lonnie Bookbinder, west coast regional director, is coordinating the research on behalf of Calvert Research LLC.

The study will center on the hypothesis that targeting siRNA-containing pharmaceutical nanocarriers, such as liposomes, with breast tumor-specific phage proteins may significantly enhance their anti-cancer activity. "This particular study was selected after an extensive nationwide effort to research numerous potential delivery technologies," stated Dr. Bookbinder. He continued by adding: "Calvert Research LLC looks forward to advancing science through this partnership with Auburn University and Dr. Petrenko."

"I am very pleased to collaborate with Calvert," Dr. Petrenko said. "Their experts first recognized that the merging of phage nanobiotechnology developed at Auburn with genomics can contribute vigorously to different areas of medicine, specifically in the area of targeted cancer therapy. I believe the new concept of phage-driven drug-delivery, which we explore in our partnership program, will demonstrate its power and vitality in the near future."

"This is an exciting opportunity for Auburn to contribute to the advancement of drug delivery technologies. This partnership with Calvert Research represents another example of how our college is working with Auburn's Office of Technology Transfer to market our faculty's discoveries," said Dr. Timothy R. Boosinger, dean.

"The Auburn project fits our plans to invest in novel therapeutic approaches that will advance clinical development of new drug compounds. We share the belief that future pharmaceuticals and biologicals will have targeted delivery," explained Russ McLauchlan, CEO of Calvert Holdings Inc. "Our alliance with Auburn University gives us a position in this growing field."

Scheduled to conclude in April 2009, the study's results will be published by Auburn University.

About Calvert Research LLC:
Calvert Research Institute was formed to bridge the gap in the early-stage drug and device development cycle. The group has implemented an innovative model of strategic partnering and can utilize the virtual nature of a consortium of specialized companies and services so that investment communities and start-ups both achieve their goals.

About Auburn University:
For more news about Auburn University, visit http://wireeagle.auburn.edu/. In-depth reporting, including multimedia features and downloadable photographs for media use, can be found at http://www.ocm.auburn.edu/newsmakers/.    Auburn University has provided instruction, research, and outreach to benefit the state and nation for more than 150 years, and is among a distinctive group of universities designated as Land, Sea, and Space Grant institutions. Auburn makes a nearly $5 billion economic contribution to the state each year, has more than 250,000 graduates, and provides 130 degree programs to more than 24,000 graduate and undergraduate students.

About Calvert Holdings Inc.:
Formed in 1996, Calvert Holdings, Inc. (www.calvertholdings.com) is a privately-held company consisting of a diverse portfolio of companies including the following: Calvert Labs, Calvert Research, Calvert BioCapital, Calvert Creative, Carolina Securities, and Calvert Cafe.

Calvert Holdings is a company of people who are passionately engaged in contributing to the future well being of the planet we live on. By analyzing how emerging discoveries and current trends will affect future global needs, we position resources and apply our skills to meet them.

###

Read the full story at http://www.prweb.com/releases/2008/10/prweb1516834.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Anti-Stem-Cell-Research Ad Ignores Facts
2. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
3. Researchers show how to stamp nanodevices with rubber molds
4. Case Western Reserve University researcher improves LCDs with 3-D nanoimaging process
5. Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
6. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
7. Food and Beverage Giant Joins Kannapolis Research Center
8. Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production
9. RSCI Announces Two Additions to Its Science Advisory Board, Calling for More Stem Cell Research on Diabetes
10. New research field promises radical advances in optical technologies
11. Swedish in Seattle Unveils State-of-the-Art Brain Tumor Center Combining Advanced Treatment With Innovation in Research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Calvert Research and Auburn University Announce Joint Venture
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):